Context Management of locally recurrent prostate cancer after definitive radiotherapy
remains controversial due to the perceived high rates of severe genitourinary (GU) and …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, hel** to …

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers
targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical …

After prostate malignancy diagnosis, precise determination of disease extent are
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …

Context Prostate-specific membrane antigen (PSMA) is a promising molecular target for
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …

Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients, as
recurrence localization guides subsequent therapies. The use of PET with prostate-specific …

Since the development of fibroblast activation protein–targeted radiopharmaceuticals, 68Ga-
fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for …

Prostate cancer is the second leading cause of cancer-related deaths in men in the United
States. Imaging techniques such as CT, MRI, and bone scans have traditionally been used …

Over the last couple of decades, gallium-68 (68Ga) has gained a formidable interest for PET
molecular imaging of various conditions, from cancer to infection, through cardiac …

Despite advances in the screening and treatment of prostate cancer, the therapy options
available, particularly for later stages of the disease, remain limited, and the treatment …